



Technology Advisory Committee C Interests Register Brolucizumab for treating diabetic macular oedema [ID3902]

Publication Date: 31/08/2022


Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	In 2020 Mr Chambers helped co-ordinate a training programme run by the University of Utrecht in Real World Evidence for Roche, manufacturer of a possible comparator therapy, but this did not involve any specific consideration of Roche products.	N/A	13.06.2022	N/A	It was agreed his declarations would not prevent Mr Chambers from participating in discussions on this appraisal.
			In 2021-22, Mr Chambers participated in an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer).				
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas has attended paid advisory boards with Novartis, and with Roche, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis).	N/A	21.06.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.



Mr Winfried Amoaku	Clinical expert	Direct – financial	Mr Amoaku has participated in ad hoc advisory boards for AbbVie, Alcon, Alimera, Allergan, Bayer, Novartis, Pfizer and Roche for which he has received honoraria (2006-2021).	N/A	28.02.2022	N/A	It was agreed that his declarations would not prevent Mr Amoaku from providing expert advice to the committee.
			Mr Amoaku has advised Roche on current and potential future treatment pathways for Geographic Atrophy (2018-2021).				
			Mr Amoaku has received educational travel grants from Alimera, Allergan, Bayer, Novartis and Pfizer (2007- 2021).				
			Mr Amoaku is a member of the Data & Safety Monitoring Board for Bioeq FYB203-03-01 MAGELLAN-AMD: 2020- 23.				
			 the Steering Committee for Apellis (2021-23). The UK FRB! Steering Committee (2020 to date). 				
			Mr Amoaku's institution, the University of Nottingham, has received funding for research sponsored by Allergan,				



			Bausch and Lomb, Gyroscope, Novartis (including the KESTRAL study), Pfizer and Roche (2004-2021) which he has participated in. The institution has also received unconditional research grants from Allergan, Bayer and Novartis.				
		Indirect – financial	Mr Amoaku is the Chair of the UK Diabetic Retinopathy Consensus (Guidelines) Group which developed Guidelines with publication costs covered by an educational grant from Allergan.				
			Mr Amoaku has received medical writing assistance provided by Prescript Communications (UK) which was partly supported by Alimera Sciences through an unrestricted grant.				
Mr Luke Nicholson	Clinical expert	Direct – financial	Mr Nicholson has received speaker fees from Bayer, Allergan and Heidelberg and research funding from Optos. He has attended an advisory board for Allergan.	N/A	19.03.2022	N/A	It was agreed that his declarations would not prevent Mr Nicholson from providing expert advice to the committee.



Stephen Scowcroft	Patient expert	Direct – financial	Mr Scowcroft's employer, the Macular Society, receives financial support from a number of pharma companies. None of the companies have direct editorial input into Macular Society information or activities.	N/A	23.03.2022	N/A	It was agreed that his declaration would not prevent Mr Scowcroft from providing expert advice to the committee.
----------------------	----------------	--------------------	---	-----	------------	-----	--